<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3939">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779375</url>
  </required_header>
  <id_info>
    <org_study_id>RISE Pediatric</org_study_id>
    <secondary_id>5U01DK094406-02</secondary_id>
    <nct_id>NCT01779375</nct_id>
  </id_info>
  <brief_title>RISE Pediatric Medication Study</brief_title>
  <acronym>RISE Peds</acronym>
  <official_title>Restoring Insulin Secretion Pediatric Medication Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RISE Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>RISE Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with&#xD;
      prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose&#xD;
      lowering will lead to recovery of beta-cell function that will be sustained after withdrawal&#xD;
      of treatment. Pediatric participants (ages 10-19) will be randomized to one of the following&#xD;
      treatment regimens: (1) metformin alone or (2) early intensive treatment with basal insulin&#xD;
      glargine followed by metformin.&#xD;
&#xD;
      The primary clinical question RISE will address is: Are improvements in ß-cell function&#xD;
      following 12 months of active treatment maintained for 3 months following the withdrawal of&#xD;
      therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal&#xD;
      of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell&#xD;
      function, insulin sensitivity and glucose tolerance and the response to an intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2013</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ß-cell Response Measured by Hyperglycemic Clamp</measure>
    <time_frame>3-months after medication washout (Month 15)</time_frame>
    <description>Clamp measures of ß-cell response, co-primary outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>M/I</measure>
    <time_frame>3-months after a medication washout</time_frame>
    <description>Clamp measure of insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACPRg</measure>
    <time_frame>3-months after a medication washout</time_frame>
    <description>First phase response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12</measure>
    <time_frame>End of active intervention (Month 12).</time_frame>
    <description>Participants had 12-months of active therapy. Secondary results at the end of active intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clamp Measure of Insulin Sensitivity</measure>
    <time_frame>End of active intervention (Month 12)</time_frame>
    <description>Participants had 12-months of active therapy. Secondary results at the end of active intervention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>OGTT Measures of ß-cell Function and Glucose Tolerance</measure>
    <time_frame>After 12 months of active treatment, and 3 and 9 months of washout</time_frame>
    <description>Measures derived the OGTT at the end of the 12 month active intervention period, and following a 3-month and 9-month washout.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Prediabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine followed by Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Glargine followed by Metformin</arm_group_label>
    <arm_group_label>Metformin alone</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <arm_group_label>Glargine followed by Metformin</arm_group_label>
    <other_name>Insulin glargine, Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fasting plasma glucose ≥90 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus&#xD;
             laboratory-based HbA1c ≤8.0% if treatment naïve. There is no upper limit for the&#xD;
             2-hour glucose on OGTT. In those taking metformin laboratory-based HbA1c must be ≤7.5%&#xD;
             if on metformin for &lt;3 months and ≤7.0% if on metformin for 3-6 months.&#xD;
&#xD;
          2. Age 10-19 years&#xD;
&#xD;
          3. Pubertal development Tanner stage &gt;1 as defined by breast stage &gt;1 in girls, and&#xD;
             testes &gt;3 cc's in boys.&#xD;
&#xD;
          4. Body mass index (BMI) ≥85th percentile but ≤50 kg/m2&#xD;
&#xD;
          5. Self-reported diabetes &lt;6 months in duration&#xD;
&#xD;
          6. Treatment with metformin for &lt;6 months preceding screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Underlying disease likely to limit life span and/or increase risk of intervention or&#xD;
             an underlying condition that is likely to limit ability to participate in outcomes&#xD;
             assessment&#xD;
&#xD;
          2. An underlying disease that affects glucose metabolism other than type 2 diabetes&#xD;
             mellitus&#xD;
&#xD;
          3. Taking medications that affect glucose metabolism, or has an underlying condition that&#xD;
             is likely to require such medications&#xD;
&#xD;
          4. Treatment with insulin for &gt;1 week preceding screening&#xD;
&#xD;
          5. Active infections&#xD;
&#xD;
          6. Renal disease (serum creatinine &gt;1.2 mg/dl) or serum potassium abnormality (&lt;3.4 or&#xD;
             &gt;5.5 mmol/l)&#xD;
&#xD;
          7. Anemia (hemoglobin &lt;11 g/dl in girls, &lt;12 g/dl in boys) or known coagulopathy&#xD;
&#xD;
          8. Cardiovascular disease, including uncontrolled hypertension defined as average&#xD;
             systolic or diastolic blood pressure &gt; 99 percentile for age or &gt;135/90, despite&#xD;
             adequately prescribed antihypertensive medications. Participants must be able to&#xD;
             safely tolerate administration of intravenous fluids required during clamp studies.&#xD;
&#xD;
          9. History of conditions that may be precipitated or exacerbated by a study drug:&#xD;
&#xD;
               1. Serum alanine transaminase (ALT) more than 3 times the upper limit of normal&#xD;
&#xD;
               2. Excessive alcohol intake&#xD;
&#xD;
               3. Sub-optimally treated thyroid disease&#xD;
&#xD;
         10. Conditions or behaviors likely to affect the conduct of the RISE Study&#xD;
&#xD;
               1. Participant and/or parents unable or unwilling to give informed consent&#xD;
&#xD;
               2. Participant and/or parents unable to adequately communicate with clinic staff&#xD;
&#xD;
               3. Another household member is a participant or staff member in RISE&#xD;
&#xD;
               4. Current, recent or anticipated participation in another intervention research&#xD;
                  project that would interfere with any of the interventions/outcomes in RISE&#xD;
&#xD;
               5. Weight loss of ≥5% of body weight in the past 3 months for any reason other than&#xD;
                  post-partum weight loss. Participants taking weight loss drugs or using&#xD;
                  preparations taken for intended weight loss are excluded.&#xD;
&#xD;
               6. Likely to move away from participating clinics in next 2 years&#xD;
&#xD;
               7. Current (or anticipated) pregnancy and lactation.&#xD;
&#xD;
               8. A pregnancy that was completed less than 6 months prior to screening.&#xD;
&#xD;
               9. Breast feeding within 6 months prior to screening.&#xD;
&#xD;
              10. Women of childbearing potential who are unwilling to use adequate contraception&#xD;
&#xD;
              11. Major psychiatric disorder that, in the opinion of clinic staff, would impede the&#xD;
                  conduct of RISE&#xD;
&#xD;
         11. Additional conditions may serve as criteria for exclusion at the discretion of the&#xD;
             local site.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine Pediatric Obesity and Type 2 Diabetes Clinic</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. Diabetes Care. 2018 Aug;41(8):1707-1716. doi: 10.2337/dc18-0243. Epub 2018 Jun 25.</citation>
    <PMID>29941498</PMID>
  </reference>
  <reference>
    <citation>RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care. 2018 Aug;41(8):1696-1706. doi: 10.2337/dc18-0244. Epub 2018 Jun 25.</citation>
    <PMID>29941497</PMID>
  </reference>
  <reference>
    <citation>Hannon TS, Kahn SE, Utzschneider KM, Buchanan TA, Nadeau KJ, Zeitler PS, Ehrmann DA, Arslanian SA, Caprio S, Edelstein SL, Savage PJ, Mather KJ; RISE Consortium. Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium. Diabetes Obes Metab. 2018 Jan;20(1):14-24. doi: 10.1111/dom.13005. Epub 2017 Jun 22. Review.</citation>
    <PMID>28493515</PMID>
  </reference>
  <reference>
    <citation>RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014;37(3):780-8. doi: 10.2337/dc13-1879. Epub 2013 Nov 5.</citation>
    <PMID>24194506</PMID>
  </reference>
  <results_reference>
    <citation>RISE Consortium. Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. 2018 Aug;41(8):1717-1725. doi: 10.2337/dc18-0787. Epub 2018 Jun 25.</citation>
    <PMID>29941500</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <results_first_submitted>August 30, 2018</results_first_submitted>
  <results_first_submitted_qc>October 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will share all research data via the NIDDK repository 2 years after final patient visit from the RISE consortium in ~2020. Data may be obtained from the repository directly.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Through the NIDDK repository in 2020, indefinitely.</ipd_time_frame>
    <ipd_access_criteria>Following NIDDK repository instructions.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01779375/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 21, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01779375/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01779375/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin Alone</title>
          <description>Metformin was titrated beginning at 500 mg/day to the maximum dose tolerated (up to 2000 mg/day).</description>
        </group>
        <group group_id="P2">
          <title>Glargine Followed by Metformin</title>
          <description>Basal insulin glargine was titrated to achieve a morning fasting blood glucose of 85-95 mg/dl and continued through 3 months after which metformin was titrated as in the Metformin alone arm and continued for 9 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin Alone</title>
          <description>Metformin was titrated beginning at 500 mg/day to the maximum dose tolerated (up to 2000 mg/day).</description>
        </group>
        <group group_id="B2">
          <title>Glargine Followed by Metformin</title>
          <description>Basal insulin glargine was titrated to achieve a morning fasting blood glucose of 85-95 mg/dl and continued through 3 months after which metformin was titrated as in the Metformin alone arm and continued for 9 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="2.1"/>
                    <measurement group_id="B2" value="14.9" spread="2.0"/>
                    <measurement group_id="B3" value="14.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-hispanic white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All othe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="6.4"/>
                    <measurement group_id="B2" value="36.5" spread="6.4"/>
                    <measurement group_id="B3" value="36.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>% of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="0.6"/>
                    <measurement group_id="B2" value="5.7" spread="0.6"/>
                    <measurement group_id="B3" value="5.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109.2" spread="19.7"/>
                    <measurement group_id="B2" value="107.5" spread="14.1"/>
                    <measurement group_id="B3" value="108.3" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour OGTT glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184.2" spread="50.2"/>
                    <measurement group_id="B2" value="183.5" spread="44.5"/>
                    <measurement group_id="B3" value="183.9" spread="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ß-cell Response Measured by Hyperglycemic Clamp</title>
        <description>Clamp measures of ß-cell response, co-primary outcomes</description>
        <time_frame>3-months after medication washout (Month 15)</time_frame>
        <population>Primary analysis was on all participants able to have a M15 visit. 2 participants in the metformin alone arm decompensated at M12 and were unable to remain off treatment until M15. A sensitivity analysis including these 2 participants using 1/2 of the worst value among all other participants did not alter the results.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Alone</title>
            <description>Metformin was titrated beginning at 500 mg/day to the maximum dose tolerated (up to 2000 mg/day).</description>
          </group>
          <group group_id="O2">
            <title>Glargine Followed by Metformin</title>
            <description>Basal insulin glargine was titrated to achieve a morning fasting blood glucose of 85-95 mg/dl and continued through 3 months after which metformin was titrated as in the Metformin alone arm and continued for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>ß-cell Response Measured by Hyperglycemic Clamp</title>
          <description>Clamp measures of ß-cell response, co-primary outcomes</description>
          <population>Primary analysis was on all participants able to have a M15 visit. 2 participants in the metformin alone arm decompensated at M12 and were unable to remain off treatment until M15. A sensitivity analysis including these 2 participants using 1/2 of the worst value among all other participants did not alter the results.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Steady State C-peptide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" lower_limit="2.07" upper_limit="11.23"/>
                    <measurement group_id="O2" value="4.18" lower_limit="1.74" upper_limit="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPRmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" lower_limit="2.81" upper_limit="17.03"/>
                    <measurement group_id="O2" value="5.95" lower_limit="2.17" upper_limit="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Seemingly unrelated regression was used to compare treatment arms on the combination of insulin sensitivity (M/I as calculated from the hyperglycemic clamp) and insulin secretion (steady-state C-peptide and ACPRmax as co-primary; ACPRg as major secondary,). See statistical analysis plan for further details and R code.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>All analyses were conducted with values on a log scale and re-exponentiated for presentation.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Measures of ß-cell response were modeled simultaneously with insulin sensitivity (M/I) using 2-df seemingly unrelated regression models.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>M/I</title>
        <description>Clamp measure of insulin sensitivity</description>
        <time_frame>3-months after a medication washout</time_frame>
        <population>All participants with a Month 15 visit</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Alone</title>
            <description>Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).&#xD;
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Glargine Followed by Metformin</title>
            <description>Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.&#xD;
Metformin&#xD;
Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>M/I</title>
          <description>Clamp measure of insulin sensitivity</description>
          <population>All participants with a Month 15 visit</population>
          <units>x 10-5 mmol/kg/min per pmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="0.29" upper_limit="7.63"/>
                    <measurement group_id="O2" value="1.70" lower_limit="0.25" upper_limit="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were completed on a log scale and re-exponentiated for presentation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACPRg</title>
        <description>First phase response</description>
        <time_frame>3-months after a medication washout</time_frame>
        <population>Primary analysis was on all participants able to have a M15 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Alone</title>
            <description>Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).&#xD;
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Glargine Followed by Metformin</title>
            <description>Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.&#xD;
Metformin&#xD;
Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>ACPRg</title>
          <description>First phase response</description>
          <population>Primary analysis was on all participants able to have a M15 visit.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.14" upper_limit="8.56"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.15" upper_limit="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12</title>
        <description>Participants had 12-months of active therapy. Secondary results at the end of active intervention.</description>
        <time_frame>End of active intervention (Month 12).</time_frame>
        <population>Secondary analysis was on all participants with a Month 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Alone</title>
            <description>Metformin was titrated beginning at 500 mg/day to the maximum dose tolerated (up to 2000 mg/day).</description>
          </group>
          <group group_id="O2">
            <title>Glargine Followed by Metformin</title>
            <description>Basal insulin glargine was titrated to achieve a morning fasting blood glucose of 85-95 mg/dl and continued through 3 months after which metformin was titrated as in the Metformin alone arm and continued for 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12</title>
          <description>Participants had 12-months of active therapy. Secondary results at the end of active intervention.</description>
          <population>Secondary analysis was on all participants with a Month 12 visit.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Steady State C-peptide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="2.09" upper_limit="10.94"/>
                    <measurement group_id="O2" value="4.37" lower_limit="1.75" upper_limit="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPRmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" lower_limit="3.16" upper_limit="15.28"/>
                    <measurement group_id="O2" value="5.79" lower_limit="2.49" upper_limit="13.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACPRg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.10" upper_limit="11.33"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.05" upper_limit="21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were completed on a log scale and re-exponentiated for display.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clamp Measure of Insulin Sensitivity</title>
        <description>Participants had 12-months of active therapy. Secondary results at the end of active intervention.</description>
        <time_frame>End of active intervention (Month 12)</time_frame>
        <population>Secondary analysis was on all participants with a Month 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin Alone</title>
            <description>Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).&#xD;
Metformin</description>
          </group>
          <group group_id="O2">
            <title>Glargine Followed by Metformin</title>
            <description>Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.&#xD;
Metformin&#xD;
Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>Clamp Measure of Insulin Sensitivity</title>
          <description>Participants had 12-months of active therapy. Secondary results at the end of active intervention.</description>
          <population>Secondary analysis was on all participants with a Month 12 visit.</population>
          <units>x 10-5 mmol/kg/min per pmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" lower_limit="0.17" upper_limit="13.48"/>
                    <measurement group_id="O2" value="1.93" lower_limit="0.30" upper_limit="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>OGTT Measures of ß-cell Function and Glucose Tolerance</title>
        <description>Measures derived the OGTT at the end of the 12 month active intervention period, and following a 3-month and 9-month washout.</description>
        <time_frame>After 12 months of active treatment, and 3 and 9 months of washout</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the 21 month study period</time_frame>
      <desc>AEs were captured at quarterly clinical visits and SAEs were captured as they occur or when reported at a subsequent clinical visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin Alone</title>
          <description>Metformin was titrated beginning at 500 mg/day to the maximum dose tolerated (up to 2000 mg/day).</description>
        </group>
        <group group_id="E2">
          <title>Glargine Followed by Metformin</title>
          <description>Basal insulin glargine was titrated to achieve a morning fasting blood glucose of 85-95 mg/dl and continued through 3 months after which metformin was titrated as in the Metformin alone arm and continued for 9 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Tonsillectomy &amp; Adenoidectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pnemonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <description>Ewing's Sarcoma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental health hospitalization</sub_title>
                <description>Suicide ideation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Low blood sugar</sub_title>
                <description>self monitored blood glucose &lt;70 mg/dl during 3 months of glargine treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Polyuria or polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Edelstein</name_or_title>
      <organization>George Washington University Biostatistics Center</organization>
      <phone>3018819260</phone>
      <email>sharone@bsc.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

